Oral contraceptive market expands

'Yaz' maintains its status despite generic entries

Despite the introduction of generics in 2021, Yaz maintains its status as the market leader

Indications for oral contraception and menstruation-related diseases positively impact sales

The market for prescription drugs+OTCs has been growing…increasing market share remains as a task

As the oral contraceptive market expands, Yaz seems to maintain its market share despite the introduction of generics.

 

According to a report by global market research firm Research and Markets, the global oral contraceptive market is expected to grow from approximately KRW 33.8 trillion (USD 23.6 billion) in 2023 to around KRW 67.3 trillion (USD 47.1 billion) by 2028.

 

Product photo of Yaz.

The South Korean market also shows a consistent growth rate, similar to the global trend, with a market size of approximately KRW 42 billion in 2023, encompassing both prescription drugs and over-the-counter drugs.

 

Contraceptives, which contain hormones such as estrogen and progesterone, are classified into four generations.

 

The first-generation drugs have been withdrawn from the market due to side effects.

 

Second- and third-generation oral contraceptives are available as over-the-counter medications and are distributed through pharmacies.

 

The third-generation contraceptives minimize the side effects of the second-generation, such as acne, hirsutism, and weight gain.

 

Bayer's Yaz (drospirenone/ethinyl estradiol) has the largest market share.

 

In 2023 (based on IQVIA), the sales of Yaz amounted to KRW 17.4 billion, holding 41% of the market share and remaining as the No.1 drug in the market.

 

After obtaining domestic approval in 2008, Yaz has been increasingly prescribed over the past 15 years.

 

Contrary to expectations for heightened competition following the patent expiration of Yaz in 2020, it is meaningful that Yaz has maintained its status as the market leader.

 

5-year sales trend of Bayer

The five-year sales of Yaz amounted to ▲KRW 14.4 billion in 2019 ▲KRW 15.9 billion in 2020 ▲peaked at KRW 19.8 billion in 2021, and slightly decreased to KRW 17.5 billion in 2022.

 

Although the sales declined due to the introduction of generics, the original product seems to maintain its impact in the market.

 

Currently, generic versions of Yaz are available as ▲Hyundai Pharm's Yaroz ▲GL Pharma's Plan-A ▲Alvogen Korea's Gvez ▲TheU Pharmaceuticals' Yamiz ▲Kwang-dong Pharm's Esleesi.

 

Besides Yaroz generating KRW 2.1 billion last year, the rest of the generics have not had a significant impact in the market.

 

The analysis is Yaz's impact stems from being the fourth-generation original oral contraceptive as well as having indications for various menstruation-related conditions, such as ▲dysmenorrhea ▲premenstrual dysphoric disorder, and ▲moderate acne treatment.

 

2023 sales report of Yaz and Yaz generics: from the top, Yaz, Yaroz, Plan-A, Gvez (unit: KRW 100 million, source: IQVIA).

The number of patients with menstruation-related conditions in South Korea has been steadily increasing over the past five years.

 

Dysmenorrhea showed an increase of approximately 85% (162,020 in 2017→299,115 in 2022), while premenstrual dysphoric disorder (PMDD) increased by approximately 34% (11,442 in 2017→15,296 in 2022).

 

Regarding this, Bayer emphasizes that they have obtained results of Yaz from real-world studies involving 410 patients with dysmenorrhea.

 

This study demonstrated that short-term and long-term administration of Yaz immediately relieved pain and symptoms and recovered endometrial thickness to normal.

 

Additionally, in a real-world study conducted at 68 domestic hospitals involving 770 healthy women aged 18–50 who visited gynecologists for contraception regardless of premenstrual dysphoric disorder status, 92.3% of participants reported an improvement in premenstrual dysphoric disorder symptoms after six cycles of treatment with Yaz.

 

Expert analysis indicates that real-world data (RWD) from various studies have impacted the prescription of the drug, considering that the contraception and menstruation-related diseases require long-term administration.

 

"Menstruation diseases, such as dysmenorrhea, significantly impact women's lives, and the disease prevalence rate is increasing, requiring more attention to treatments," Dr.

 

Yun Bo Hyun, Professor of Severance Hospital's Department of Obstetrics and Gynecology, said.

 

"The disease requires long-term and frequent treatments.

 

When choosing a treatment option, patients' conditions must be considered for potential incompatibility in combining oral contraceptives." Dr.

 

Yun added, "Yaz has 15 years of prescription history in South Korea, and it is a treatment option with confirmed benefits of improving symptoms related to menstrual diseases and established safety based on numerous studies."